- Chemotherapy and radiotherapy induced nausea and vomiting
- Prevention and treatment of post-operative nausea and vomiting
Adults Population
- Chemotherapy and radiotherapy (in adults): 8-32 mg Ondansetron/day
- Post-operative nausea and vomiting (In adult): Single dose of 4mg Ondansetron
Pediatric Population
- Chemotherapy and radiotherapy induced nausea and vomiting (CINV): The dose for CINV can be calculated based on body weight. Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals. The total daily dose must not exceed adult dose of 32 mg.
- Post-operative nausea and vomiting in children aged ≥ 1 month and adolescents: Single dose of Ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anesthesia.
- Hypersensitivity to Ondansetron or other selective 5-HT3 receptor antagonists (Granisetron or Dolasetron).
- Concomitant use with Apomorphine (use to treat Parkinson’s disease).
- Hypersensitivity reactions to other selective 5-HT3 receptor antagonists.
- Avoid Ondansetron in patients with congenital long QT syndrome.
- Patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmia or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.
- Hypokalaemia and hypomagnesaemia should be corrected prior to Ondansetron administration.
- Headache
- Fever
- Cold feeling
- Lightheadacheness
- Dizziness
- Drowsiness
- Tiredness
- Diarrhea
- Constipation
- Itching
- Numbness
- Tingling
- Injection site reactions (redness, pain, burning).
Store at 20 to 25°C Product may also be stored in a refrigerator, 2 to 8°C.
ONDERON Injection 2ml: 10×2 ml Ampoule
ONDERON Injection 4ml: 5×4 ml Ampoule
